$1.33 Billion is the total value of Ikarian Capital, LLC's 151 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | SAREPTA THERAPEUTICS INCcall | $10,036,000 | -24.2% | 102,600 | 0.0% | 0.76% | -64.8% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $2,335,000 | -27.5% | 157,468 | 0.0% | 0.18% | -66.3% | |
| ASMB | ASSEMBLY BIOSCIENCES INCput | $2,225,000 | -27.5% | 150,000 | 0.0% | 0.17% | -66.4% | |
| CHRS | COHERUS BIOSCIENCES INCcall | $1,364,000 | -9.9% | 84,100 | 0.0% | 0.10% | -58.0% | |
| BLU | BELLUS HEALTH INC NEW | $891,000 | +42.6% | 63,721 | 0.0% | 0.07% | -33.7% | |
| VKTX | VIKING THERAPEUTICS INC | $590,000 | -41.7% | 126,159 | 0.0% | 0.04% | -73.2% | |
| PGNX | PROGENICS PHARMACEUTICALS IN | $497,000 | -25.4% | 130,845 | 0.0% | 0.04% | -65.7% | |
| AXGT | AXOVANT GENE THERAPIES LTD | $461,000 | -52.3% | 188,884 | 0.0% | 0.04% | -77.7% | |
| DRNA | DICERNA PHARMACEUTICALS INCcall | $285,000 | -16.4% | 15,500 | 0.0% | 0.02% | -61.8% | |
| OBSV | OBSEVA SA | $199,000 | -36.8% | 82,573 | 0.0% | 0.02% | -70.6% | |
| AEZS | AETERNA ZENTARIS INC | $60,000 | -43.9% | 117,443 | 0.0% | 0.01% | -70.6% | |
| MITO | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $47,000 | -61.8% | 37,597 | 0.0% | 0.00% | -80.0% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $46,000 | +21.1% | 111,445 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.